Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference.
The company's management will deliver their presentation on January 15th, 2025, at 4:30 p.m. PT. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.
Terns Pharmaceuticals (Nasdaq: TERN), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di candidati a piccole molecole per malattie gravi tra cui oncologia e obesità, ha annunciato la sua prossima partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan.
La direzione dell'azienda presenterà il proprio intervento il 15 gennaio 2025, alle 16:30 PT. Gli investitori e le parti interessate possono accedere a una trasmissione in diretta della presentazione tramite la pagina delle relazioni con gli investitori all'indirizzo http://ir.ternspharma.com. La registrazione della presentazione sarà disponibile sul sito web dell'azienda per un periodo minimo di 30 giorni dopo l'evento.
Terns Pharmaceuticals (Nasdaq: TERN), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de candidatos a pequeñas moléculas para enfermedades graves, incluyendo oncología y obesidad, ha anunciado su próxima participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan.
La gestión de la empresa dará su presentación el 15 de enero de 2025, a las 4:30 p.m. PT. Los inversores y partes interesadas pueden acceder a una transmisión web en vivo de la presentación a través de la página de relaciones con inversores en http://ir.ternspharma.com. La grabación de la presentación estará disponible en el sitio web de la empresa durante un mínimo de 30 días después del evento.
Terns Pharmaceuticals (Nasdaq: TERN), 심각한 질병, 특히 종양학 및 비만을 위한 저분자 후보 물질 개발에 집중하는 임상 단계의 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다.
회사의 경영진은 2025년 1월 15일 오후 4시 30분 PT에 발표를 진행할 것입니다. 투자자와 이해관계자는 http://ir.ternspharma.com의 투자자 관계 페이지를 통해 발표의 생중계 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 이후 최소 30일 동안 회사 웹사이트에서 제공될 것입니다.
Terns Pharmaceuticals (Nasdaq: TERN), une entreprise biopharmaceutique en phase clinique axée sur le développement de candidats à petites molécules pour des maladies graves telles que l'oncologie et l'obésité, a annoncé sa prochaine participation à la 43ème Conférence Annuelle de J.P. Morgan sur la Santé.
La direction de l'entreprise présentera son intervention le 15 janvier 2025 à 16h30 PT. Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la page des relations investisseurs à l'adresse http://ir.ternspharma.com. L'enregistrement de la présentation restera disponible sur le site de l'entreprise pendant un minimum de 30 jours après l'événement.
Terns Pharmaceuticals (Nasdaq: TERN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von niedermolekularen Produktkandidaten für schwere Krankheiten, einschließlich Onkologie und Fettleibigkeit, konzentriert, hat seine bevorstehende Teilnahme an der 43. jährlichen JP Morgan Healthcare-Konferenz bekannt gegeben.
Das Management des Unternehmens wird seine Präsentation am 15. Januar 2025 um 16:30 Uhr PT halten. Investoren und Interessierte können über die Investor Relations-Seite unter http://ir.ternspharma.com auf einen Livestream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird mindestens 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar bleiben.
- None.
- None.
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT.
A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
When is Terns Pharmaceuticals (TERN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Terns Pharmaceuticals' (TERN) J.P. Morgan Healthcare Conference presentation?
How long will Terns Pharmaceuticals' (TERN) J.P. Morgan presentation replay be available?
What therapeutic areas is Terns Pharmaceuticals (TERN) currently focusing on?
